Calidi Biotherapeutics, Inc.CLDI
Price (close)
$1.13
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$17.5M
Dividend yield
—
1-year total return
-95.1%
Net margin
—
Revenue growth
—
Debt / equity
0.21x
What Calidi Biotherapeutics, Inc. does.
are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic
medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for
systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $45,000 | — | — | — |
| Net income | — | -$25.4M | -$29.2M | -$22.1M | -$19.9M |
More on CLDI.
- Calidi Biotherapeutics, Inc. summary
- Calidi Biotherapeutics, Inc. financial statements
- Calidi Biotherapeutics, Inc. key metrics
- Calidi Biotherapeutics, Inc. health scores and style box
- Calidi Biotherapeutics, Inc. earnings
- Calidi Biotherapeutics, Inc. dividends
- Calidi Biotherapeutics, Inc. valuation
- Calidi Biotherapeutics, Inc. ownership and insiders
- Calidi Biotherapeutics, Inc. peers
Figures from Calidi Biotherapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.